Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.

Abstract

An intraperitoneal injection of GK-2 (dipeptide mimetic of nerve growth factor, 0.01-5.00 mg/kg) 24 h before the adverse exposure reduced the severity of haloperidol-induced catalepsy in rats. This agent retained the activity after oral administration in a dose of 10 mg/kg. An intraperitoneal injection of GK-2 in a dose of 1 mg/kg reduced the severity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in mice. Administration of GK-2 45 min after haloperidol treatment was also followed by a decrease in the degree of catalepsy. The repeated intraperitoneal treatment with GK-2 in a dose of 1 mg/kg after intrastriatal injection of 6-hydroxydopamine was shown to prevent the development of apomorphine-induced rotations in rats.

• Authors: P Yu Povarnina, T A Gudasheva, O N Vorontsova, N A Bondarenko, S B Seredenin
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 151 Issue 6 Pg. 690-3 (Oct 2011) ISSN: 1573-8221 [Electronic] United States
• PMID: 22485209 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Dipeptides
• bis(N-succinyl-glutamyllysin)hexamethylenediamine
• Oxidopamine
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
• Haloperidol

Topics

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology)
• Animals
• Antiparkinson Agents (therapeutic use)
• Catalepsy (chemically induced, drug therapy)
• Dipeptides (therapeutic use)
• Haloperidol (pharmacology)
• Male
• Mice
• Mice, Inbred C57BL
• Oxidopamine (pharmacology)
• Parkinsonian Disorders (chemically induced, drug therapy)
• Rats